Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2N76V)

Drug Name

YP-008 Drug Info

Synonyms

RPL-228; Cyclopentenone prostaglandin mimetic (PGM) (topical, psoriasis), York Pharma; Natural-defence-prostanoid mimetic (topical, psoriasis), York Pharma

Indication

Disease Entry	ICD 11	Status	REF
Psoriasis vulgaris	EA90	Terminated	[1]

Cross-matching ID

TTD Drug ID: DM2N76V

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Prostaglandin receptor (PTGR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bimatoprost	DMX0E5B	Alopecia	ED70	Approved	[3]
Unoprostone	DMXNR04	Glaucoma/ocular hypertension	9C61	Approved	[4]
Iclaprim	DM7YNV9	Bacterial infection	1A00-1C4Z	Phase 3	[5]
JB991	DMKU6MW	Skin infection	1F28-1G0Z	Phase 2	[6]
Taprostene	DMA4WY5	Thrombosis	DB61-GB90	Discontinued in Phase 3	[7]
ZD-4953	DM5UCHW	Pain	MG30-MG3Z	Discontinued in Phase 2	[8]
TEI-6122	DM3F5E0	Diabetic complication	5A2Y	Discontinued in Phase 2	[9]
YP-009	DMPXLG2	Solid tumour/cancer	2A00-2F9Z	Terminated	[10]
IP-1200	DMIX7CP	Erectile dysfunction	HA01.1	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin receptor (PTGR)	TT9B4N3	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026448)
2	CA patent application no. 841416, Method of selecting therapeutic indications.
3	Bimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptors. Curr Eye Res. 2009 Mar;34(3):184-95.
4	Comparison of the vasoactive effects of the docosanoid unoprostone and selected prostanoids on isolated perfused retinal arterioles. Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1499-504.
5	Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011; 5: 667-677.
6	US patent application no. 2006,0041,016, Composition and method for the treatment of psoriasis.
7	Partial agonism of taprostene at prostanoid IP receptors in vascular preparations from guinea-pig, rat, and mouse. J Cardiovasc Pharmacol. 2004 Jun;43(6):795-807.
8	WO patent application no. 2013,1675,82, Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease.
9	The effect of a synthetic 7-thiaprostaglandin E1 derivative, TEI-6122, on monocyte chemoattractant protein-1 induced chemotaxis in THP-1 cells.. Br J Pharmacol. 1995 October; 116(4): 2298-2302.
10	YP 009 York Pharma pc preclinical, UK(cancer), R & D Focus Drug News, November 12, 2007
11	Clinical pipeline report, company report or official report of Immunologic.